Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-07-19
1998-04-14
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
057391513
ABSTRACT:
Disclosed herein is a method of eliciting an antiemetic effect by administering optically pure (+) isomer of norcisapride.
REFERENCES:
patent: 4962115 (1990-10-01), Van Daele
patent: 5057525 (1991-10-01), Van Daele
patent: 5114714 (1992-05-01), Young et al.
patent: 5114715 (1992-05-01), Young et al.
patent: 5137896 (1992-08-01), Van Daele
Porsius, A.J. and van den Brink, G., "Farmacotoets 6A," Farmacotherapie, 129:9:214-217 (1994).
Schiavi, G.B., et al., "Identification of Serotonin 5-HT.sub.4 Recognition Sites in the Porcine Caudate Nucleus by Radioligand Binding," Neuropharmacology, 33:543-549 (1994).
Krejs, G.J. "Serotonine Intestinale, une Cible Therapeutique," Med. Chir. Dig., 22:7:415-416 (1993).
Zuccato, E., et al., "The Effects of S(-) and R(+) Sulpiride, Metoclopramide, Cisapride and Domperidone on the Small Intestine Suggest DA.sub.2 -Receptors are Involved in the Control of Small Intestinal Transit Time in Rats," Pharmacological Research, 26:2:179-185 (1992).
Gladziwa, U., et al., "Pharmacokinetics and Pharmacodynamics of Cisapride in Patients Undergoing Hemodialysis," Clinical Pharmacology, 50:6:673-681 (1991).
Gullikson, G.W., et al., "Relationship of Serotonin-3 Receptor Antagonist Acitivity to Gastric Emptying and Motor-Stimulating Actions of Prokinetic Drugs in Dogs," Journal of Pharmacology and Experimental Therapeutics, 258(1):103-110 (1991).
Frazer, A., et al., "Subtypes of Receptors for Serotonin," Annual Rev. of Pharmacology and Toxicology, 30:307-348 (1990).
Schapira, M., et al., "The Current Status of Gastric Prokinetic Drugs," Acta Gastroenterolog. Belg. LIII:446-457 (1990).
Clarke, D.E., et al., "The 5-HT.sub.4 Receptor: Naughty, but Nice," Trends in Pharmacological Sciences, 10:385-386 (1989).
Craig, D.A. and Clark, D.E., "5-Hydroxytryptamine and Cholinergic Mechanisms in Guinea-pig lleum," Brit. J. Pharmacol., 96:247 (1989).
Dumuis, A., et al., "The Gastrointestinal Prokinetic Benzamide Derivatives are Agontist at the Non-Classical 5-HT Receptor (5-HT.sub.4) Positively Coupled to Adenylate Cyclase in Neurons," N.S. Arch. Pharmacol., 340:403-410 (1989).
Jamali, F., et al., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls," Journal of Pharmaceutical Sciences, 78(9):695-715 (1989).
Nemeth, P.R. and Guillikson, G.W., "Gastrointestinal Motility Stimulating Drugs and 5-HT Receptors on Myenteric Neurons," European Journal of Pharmacology, 166:387-391 (1989).
Nemeth, P.R. and Guillikson, G.W., Chemical Abstracts, vol. 111, No. 19, Abs. No. 167161a (1989).
Scrip's New Product Review No. 32 Cisapride, PJB Publications Ltd. (Apr. 1989).
Barnes, N.M., et al, "Identification of 5-HT.sub.3 Recognition Sites in the Ferret Area Postrema," J. Pharm. Pharmacol., 40:586-588 (1988).
Decktor, D.L., et al., "Effect of Metoclopramide, Bethanechol and the Cholecystokinin Receptor Antagonist, L-364,718, on Gastric Emptying in the Rat," Eur. J. Pharmacol., 147:313-316 (1988).
Lauwers, W., et al., "Identificatin of a Biliary Metabolite of Cisapride," Biomedical and Environmental Mass Spectrometry, 15:323-328 (1988).
Meuldermans, W., et al., "Excretion and Biotransformation of Cisapride in Dogs and Humans After Oral Adminstration," Drug Metabolism and Disposition, 16:3:403-409 (1988).
Meuldermans, W., et al., "Excretion and Biotransformation of Cisapride in Rats After Oral Administration," Drug Metabolism and Disposiion, 16:3:410-419 (1988).
Van Peer, A., et al., "Clinical Pharmacokinetics of Cisapride," Progress in the Treatment of Gastrointestinal Motility Disorders: The Role of Cisapride, Proceedings of a Symposium in Frankfurt Excerpta Medica, pp. 23-29 (1988).
Barone, J.A., et al., "Bioavailability of Three Oral Dosage Forms of Cisapride, a Gastrointestinal Stimulant Agent,"0 Clinical Pharmacy, 6:640-645 (1987).
Costall, B., et al., "Emesis Induced by Cisplatin in the Ferret as a Model for the Detection of Anti-Emetic Drugs," Neuropharmacology, 26:1321-1326 (1987).
Stacher, G., et al., "Effects of Oral Cisapride on Interdigestive Jejunal Motor Activity, Psychomotor Function, and Side-Effect Profile in Healthy Man," Digestive Disease and Sciences, 32(11):1223-1230 (1987).
Van Daele, G.H.P., et al., "Synthesis of Cisapride, a Gastrointestinal Stimulant Derived From Cis-4-Amino-3-Methoxypiperidine," Drug Development Research, 8:225-232 (1986).
Fernandez, A.G., and Massingham R., "Peripheral Receptor Populations Involved in the Regulation of Gastrointestinal Motility and the Pharmacological Actions of Metoclopramide-like Drugs," Life Sci., 36:1-14 (1985).
Schuurkes, J.A.J., et al., "Motor-Stimulating Properties of Cisapride on Isolated Gastrointestinal Preparations of the Guinea Pig, " J. Pharmacol. Exp. Ther., 234:775-783 (1985).
Williams, C.L. and Burks, T.F., "Cisapride Increases Gastric Emptying Without Affecting Small or Large Bowel Transit," Proc. West. Pharmacol. Soc., 28:47-50 (1985).
Milo, R., "Non-Cholinergic, Non-antidopaminergic Treatment of Chronic Digestive Symptoms Suggestive Of A Motility Disorder: A Two-Step Pilot Evaluation of Cisapride," Curr. Therapeutic Research, 36:5:1053-1062 (1984).
Reyntjens, A., et al., "Clinical Pharmacological Evidence For Cisapride's Lack of Antidopaminergic or Direct Cholinergic Properties," Current Therapeutic Research, 36:5:1045-1052 (1984).
Lavrijsen, K., et al., "The Role of CYP3A4 in the In-Vitro Metabolism of Cisapride in Human Liver Microsomes and In-Vitro and In Vivo Interactions of Cisapride with Co-Administered Drugs," Dept. of Pharmacokinetics and Drug Metabolism, Janssen Research Foundation. (1988).
Jerussi Thomas P.
McCullough John R.
Jarvis William R. A.
Sepracor Inc.
LandOfFree
Method for treating emesis and central nervous system disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating emesis and central nervous system disorders , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating emesis and central nervous system disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-634978